These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9695716)

  • 1. Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers.
    Gambús PL; Schnider TW; Minto CF; Youngs EJ; Billard V; Brose WG; Hochhaus G; Shafer SL
    Clin Pharmacol Ther; 1998 Jul; 64(1):27-38. PubMed ID: 9695716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of high intravenous doses of dynorphin A(1-13) on tail flick latency and central nervous system histology in rats.
    Pentel PR; Wananukul W; Hooke LP; Jones CR; Hatsukami D; Anderson WR; Lee NM
    Pharmacol Biochem Behav; 1995; 51(2-3):387-90. PubMed ID: 7667358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the kappa-opioid dynorphin A(1-13) on learning and memory in mice.
    Ukai M; Itoh J; Kobayashi T; Shinkai N; Kameyama T
    Behav Brain Res; 1997 Feb; 83(1-2):169-72. PubMed ID: 9062678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of dynorphin A (1-13) and dynorphin A (1-10) amide on stress-induced analgesia.
    Starec M; Rosina J; Málek J; Krsiak M
    Physiol Res; 1996; 45(6):433-8. PubMed ID: 9085373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II, multicenter, randomized, double-blind, placebo-controlled crossover study of CJC-1008--a long-acting, parenteral opioid analgesic--in the treatment of postherpetic neuralgia.
    Wallace MS; Moulin D; Clark AJ; Wasserman R; Neale A; Morley-Forster P; Castaigne JP; Teichman S
    J Opioid Manag; 2006; 2(3):167-73. PubMed ID: 17319450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynorphin A-(1-13) potently improves scopolamine-induced impairment of passive avoidance response in mice.
    Ukai M; Kobayashi T; Shinkai N; Shan-Wu X; Kameyama T
    Eur J Pharmacol; 1995 Feb; 274(1-3):89-93. PubMed ID: 7768285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynorphin A (1-13) in the brain suppresses epinephrine-induced ventricular premature complexes and ventricular tachyarrhythmias.
    Rabkin SW
    Regul Pept; 1992 Sep; 41(2):95-107. PubMed ID: 1279757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecally administered dynorphin-(1-17) modulates morphine-induced antinociception differently in morphine-naive and morphine-tolerant rats.
    Schmauss C; Herz A
    Eur J Pharmacol; 1987 Mar; 135(3):429-31. PubMed ID: 2884124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of systemically administered dynorphin A(1-17) in rhesus monkeys.
    Butelman ER; Harris TJ; Perez A; Kreek MJ
    J Pharmacol Exp Ther; 1999 Aug; 290(2):678-86. PubMed ID: 10411578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid receptor agonists selective for mu and kappa receptors attenuate methamphetamine-induced behavioral sensitization in the mouse.
    Toyoshi T; Ukai M; Kameyama T
    Biol Pharm Bull; 1996 Mar; 19(3):369-74. PubMed ID: 8924903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human pharmacology of the opioid neuropeptide dynorphin A(1-13).
    Greenwald MK; Stitzer ML; Haberny KA
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1154-63. PubMed ID: 9190848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of acute morphine tolerance by corticotropin-releasing factor and dynorphin A in the mouse spinal cord.
    Song SH; Takemori AE
    Life Sci; 1992; 51(2):107-11. PubMed ID: 1352026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: effect of different routes of administration.
    Brugos B; Arya V; Hochhaus G
    AAPS J; 2004 Dec; 6(4):e36. PubMed ID: 15760101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulators of pain in the spinal cord.
    Jen MF; Lu CH; Huang L; Han JS
    NIDA Res Monogr; 1986; 75():457-60. PubMed ID: 2893278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of morphine-induced EEG and behavioral effects by dynorphin A-(1-13) in non-tolerant and morphine-tolerant rats.
    Hong O; Young GA; Khazan N
    Neuropharmacology; 1988 Aug; 27(8):807-12. PubMed ID: 2905786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of microinjection of dynorphin fragments into the nucleus of the solitary tract (NTS) are mediated by non-opioid mechanisms.
    Fan L; McIntosh TK
    Brain Res; 1993 Sep; 623(1):110-6. PubMed ID: 8106118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of dynorphin A (1-13) in conscious rats and its modulation of morphine bradycardia over time.
    Glatt CE; Kenner JR; Long JB; Holaday JW
    Peptides; 1987; 8(6):1089-92. PubMed ID: 2894646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opiate and alpha receptor antagonists block the pressor responses of conscious rats given intravenous dynorphin.
    Thornhill JA; Gregor L; Saunders WS
    Peptides; 1989; 10(1):171-7. PubMed ID: 2568623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphine-like discriminative stimulus effects of opioid peptides: possible modulatory role of D-Ala2-D-Leu5-enkephalin (DADL) and dynorphin A (1-13).
    Ukai M; Holtzman SG
    Psychopharmacology (Berl); 1988; 94(1):32-7. PubMed ID: 2894701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.